Cargando…
Prolyl oligopeptidase inhibition reduces PolyQ aggregation and improves cell viability in cellular model of Huntington’s disease
Autores principales: | Norrbacka, Susanna, Lindholm, Dan, Myöhänen, Timo T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850970/ https://www.ncbi.nlm.nih.gov/pubmed/31565846 http://dx.doi.org/10.1111/jcmm.14675 |
Ejemplares similares
-
Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo
por: Svarcbahs, Reinis, et al.
Publicado: (2018) -
Prolyl oligopeptidase inhibition reduces alpha‐synuclein aggregation in a cellular model of multiple system atrophy
por: Cui, Hengjing, et al.
Publicado: (2021) -
Nonpeptidic
Oxazole-Based Prolyl Oligopeptidase Ligands
with Disease-Modifying Effects on α-Synuclein Mouse Models
of Parkinson’s Disease
por: Kilpeläinen, Tommi P., et al.
Publicado: (2023) -
Coaggregation of polyglutamine (polyQ) proteins is mediated by polyQ-tract interactions and impairs cellular proteostasis: Coaggregation of polyQ proteins
por: Hong, Jun-Ye, et al.
Publicado: (2023) -
Prolyl Oligopeptidase Regulates Dopamine Transporter Oligomerization and Phosphorylation in a PKC- and ERK-Independent Manner
por: Julku, Ulrika H., et al.
Publicado: (2021)